Floatz logo

Metformin

BRCA1 Mutation Carrier

Alliance for Clinical Trials in OncologySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the BRCA1 Mutation Carrier cohort.

Asset / SponsorPhaseRating
Olaparib
VA Office of Research and Development
Phase 3BB
Carboplatin
VA Office of Research and Development
Phase 2BB
Letrozole
UNICANCER
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
University Health Network, Toronto
Phase 2/3BB
Veliparib
AbbVie
Phase 2BB

View all 26 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →